MedGenome Raises $47.5M to Accelerate Genomic Diagnostics in Emerging Markets

MedGenome, a leading player in genomic diagnostics and research, has secured $47.5 million in a Series E funding round. The investment was led by Maj Invest and Novo Holdings, with continued support from existing investor Sofina.

Headquartered in Bengaluru, the company stated that the fresh capital will be used to expand access to its genomics and diagnostics platforms across India and other emerging markets. This move underscores a broader shift towards precision medicine and personalized healthcare solutions in the region.

CEO Vedam Ramprasad noted that the funding reflects increasing adoption of genomics in preventive and personalized care. MedGenome currently offers a comprehensive portfolio of over 1,300 genetic tests, covering oncology, rare and inherited diseases, reproductive health, infectious diseases, and wellness screening.

With this new backing, the company aims to further democratize genomic testing and reinforce its leadership in the rapidly evolving space of precision diagnostics.